Psoriasis | Disease Landscape and Forecast | G7 | 2019

The psoriasis therapy market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12/23 inhibitor ustekinumab (Janssen’s Stelara) is being challenged by the introduction of the highly effective IL-17 inhibitors. In particular, the uptake of secukinumab (Novartis’s Cosentyx) has been remarkable in the first two years of its launch, but the agent faces competition from the newer IL-17 inhibitors—ixekizumab (Eli Lilly’s Taltz) and brodalumab (Valeant/LEO Pharma/Kyowa Hakko Kirin’s Siliq/Kyntheum/Lumicef). With the approval and launch of Janssen’s IL-23 inhibitor, guselkumab (Tremfya), another effective drug class has been introduced into this increasingly competitive market. Additionally, the landscape for the established biologics will change further with the increasing availability and use of biosimilars.

  • How do interviewed KOLs view the efficacy and safety of the IL-17 inhibitors (Cosentyx, Taltz, Siliq/Lumicef, bimekizumab), and where are/will these agents be positioned in the psoriasis treatment algorithm?
  • What will be the impact of the IL-23 inhibitors (guselkumab, Merck & Co./Almirall/Sun Pharma’s tildrakizumab, AbbVie/Boehringer Ingelheim’s risankizumab, Eli Lilly’s mirikizumab), and how will they fare in the competitive psoriasis market?
  • How is the oral agent apremilast (Celgene’s Otezla) used for psoriasis treatment, and what are the other promising emerging oral therapies?
  • How fast will the uptake of biosimilars occur in psoriasis, and which brands will experience the most erosion in patient share and sales?

Scope:

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: 20 country-specific interviews with thought leaders.

Epidemiology: Number of total, diagnosed, and drug-treated prevalent cases of psoriasis; number of diagnosed prevalent cases of psoriasis by severity.

Emerging therapies: Phase II: 14drugs; Phase III/preregistration: 7 drugs; coverage of select preclinical and Phase I products.